Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 67-71 |
| Number of pages | 5 |
| Journal | Clinical Genitourinary Cancer |
| Volume | 15 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2017 |
Fingerprint
Cite this
Incidence and Predictors of 30-Day Readmission After Robot-Assisted Radical Prostatectomy. / Moschini, M; Gandaglia, G; Fossati, Nicola; Dell'Oglio, P; Cucchiara, V; Luzzago, S; Zaffuto, E; Suardi, N; Damiano, Rocco; Shariat, SF; Montorsi, F; Briganti, A.
In: Clinical Genitourinary Cancer, Vol. 15, No. 1, 2017, p. 67-71.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Incidence and Predictors of 30-Day Readmission After Robot-Assisted Radical Prostatectomy
AU - Moschini, M
AU - Gandaglia, G
AU - Fossati, Nicola
AU - Dell'Oglio, P
AU - Cucchiara, V
AU - Luzzago, S
AU - Zaffuto, E
AU - Suardi, N
AU - Damiano, Rocco
AU - Shariat, SF
AU - Montorsi, F
AU - Briganti, A
PY - 2017
Y1 - 2017
N2 - OBJECTIVE: To evaluate the incidence and predictors of 30-day readmission in prostate cancer (PCa) patients treated with robot-assisted radical prostatectomy (RARP). PATIENTS AND METHODS: Overall, 1402 consecutive PCa patients treated with RARP at a single center between 2006 and 2013 were identified. Uni- and multivariate logistic regression analyses assessed predictors of 30-day readmission after surgery. RESULTS: Overall, 38 patients (2.7%) experienced hospital readmission within 30 days after discharge. The most common causes of rehospitalization were fever in 12 patients (31.6%), lymphoceles in 11 (28.9%), and urine leak in 6 (15.8%). By multivariable analyses, D'Amico risk group and occurrence of postoperative complications (odds ratio [OR], 2.89) represented independent predictors of 30-day readmission (all P ≤ .02). When analyzing the type of complication associated with the risk of readmission, fever (OR, 6.19; P = .01), urine leak (OR, 10.83; P <.01) and cardiocirculatory complications (OR, 18.57; P <.001) were significantly associated with 30-day readmission. CONCLUSION: Patients undergoing RARP have a relatively low risk of 30-day readmission (2.7%). The occurrence of an early postoperative complication and a higher D'Amico risk group were independent predictors of 30-day readmission. In addition, fever, urine leak, and cardiocirculatory complications are significantly associated with a higher risk of readmission. Copyright © 2016 Elsevier Inc. All rights reserved.
AB - OBJECTIVE: To evaluate the incidence and predictors of 30-day readmission in prostate cancer (PCa) patients treated with robot-assisted radical prostatectomy (RARP). PATIENTS AND METHODS: Overall, 1402 consecutive PCa patients treated with RARP at a single center between 2006 and 2013 were identified. Uni- and multivariate logistic regression analyses assessed predictors of 30-day readmission after surgery. RESULTS: Overall, 38 patients (2.7%) experienced hospital readmission within 30 days after discharge. The most common causes of rehospitalization were fever in 12 patients (31.6%), lymphoceles in 11 (28.9%), and urine leak in 6 (15.8%). By multivariable analyses, D'Amico risk group and occurrence of postoperative complications (odds ratio [OR], 2.89) represented independent predictors of 30-day readmission (all P ≤ .02). When analyzing the type of complication associated with the risk of readmission, fever (OR, 6.19; P = .01), urine leak (OR, 10.83; P <.01) and cardiocirculatory complications (OR, 18.57; P <.001) were significantly associated with 30-day readmission. CONCLUSION: Patients undergoing RARP have a relatively low risk of 30-day readmission (2.7%). The occurrence of an early postoperative complication and a higher D'Amico risk group were independent predictors of 30-day readmission. In addition, fever, urine leak, and cardiocirculatory complications are significantly associated with a higher risk of readmission. Copyright © 2016 Elsevier Inc. All rights reserved.
U2 - 10.1016/j.clgc.2016.06.002
DO - 10.1016/j.clgc.2016.06.002
M3 - Article
VL - 15
SP - 67
EP - 71
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
SN - 1558-7673
IS - 1
ER -